AR039633A2 - Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica - Google Patents
Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronicaInfo
- Publication number
- AR039633A2 AR039633A2 ARP030101259A ARP030101259A AR039633A2 AR 039633 A2 AR039633 A2 AR 039633A2 AR P030101259 A ARP030101259 A AR P030101259A AR P030101259 A ARP030101259 A AR P030101259A AR 039633 A2 AR039633 A2 AR 039633A2
- Authority
- AR
- Argentina
- Prior art keywords
- cabergoline
- prepare
- treatment
- fibromialgia
- chronic fatigue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
El uso de un compuesto de tipo cabergolina, o de una de sus sales farmacéuticamente aceptables, que es para preparar un medicamento para el tratamiento de síntomas del síndrome de fibromialgia o síndrome de fatiga crónica. Reivindicación 3: el uso de un compuesto de la reivindicación 1, caracterizado porque dicho compuesto es un compuesto de la fórmula (C) o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19895900P | 2000-04-21 | 2000-04-21 | |
US20056900P | 2000-04-28 | 2000-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039633A2 true AR039633A2 (es) | 2005-03-02 |
Family
ID=26894316
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101861A AR028355A1 (es) | 2000-04-21 | 2001-04-20 | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
ARP030101259A AR039633A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
ARP030101258A AR039632A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101861A AR028355A1 (es) | 2000-04-21 | 2001-04-20 | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101258A AR039632A2 (es) | 2000-04-21 | 2003-04-10 | Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica |
Country Status (16)
Country | Link |
---|---|
US (3) | US6448258B2 (es) |
EP (1) | EP1274430B1 (es) |
JP (1) | JP2004502650A (es) |
KR (1) | KR20040007215A (es) |
CN (3) | CN1450898A (es) |
AR (3) | AR028355A1 (es) |
AT (1) | ATE312608T1 (es) |
AU (2) | AU5311401A (es) |
BR (1) | BR0110210A (es) |
CA (1) | CA2405565A1 (es) |
DE (1) | DE60115872T2 (es) |
DK (1) | DK1274430T3 (es) |
ES (1) | ES2253370T3 (es) |
NZ (3) | NZ531172A (es) |
PE (1) | PE20011212A1 (es) |
WO (1) | WO2001081343A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
CA2404704A1 (en) * | 2000-04-21 | 2001-11-22 | David W. Robertson | Treatment of fibromyalgia and chronic fatigue syndrome |
AR033520A1 (es) * | 2000-04-27 | 2003-12-26 | Upjohn Co | (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona |
MXPA03001472A (es) * | 2000-08-16 | 2003-06-06 | Upjohn Co | Compuestos para el tratamiento de trastornos adictivos. |
AR031152A1 (es) | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
CA2500919A1 (en) * | 2002-10-04 | 2004-04-22 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
BR0314526A (pt) * | 2002-10-04 | 2005-07-26 | Pharmacia Corp | Composições farmacêuticas para o tratamento do mal de parkinson |
JP2009501184A (ja) | 2005-07-13 | 2009-01-15 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6、5−ht24としてのベンゾイミダゾール誘導体 |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
ES2332645B1 (es) * | 2009-06-30 | 2010-10-18 | Grifols, S.A. | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
DK2618826T3 (en) * | 2010-09-20 | 2016-08-01 | A Carlsson Res Ab | Phenylpiperdine FOR TREATMENT OF DEMENTIA |
EA035469B1 (ru) | 2013-03-15 | 2020-06-22 | Инсайт Холдингс Корпорейшн | Трициклические гетероциклы как ингибиторы белков бэт |
JP2016523964A (ja) | 2013-07-08 | 2016-08-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
MX2016013851A (es) | 2014-04-23 | 2017-07-14 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet). |
DE102014008742A1 (de) * | 2014-06-12 | 2015-12-17 | Daimler Ag | Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
WO2016180879A1 (en) * | 2015-05-13 | 2016-11-17 | A. Carlsson Research Ab | Treatment of debilitating fatigue |
US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
CR20220651A (es) | 2016-06-20 | 2023-01-23 | Incyte Corp | FORMAS SOLIDAS CRISTALINAS DE UN INHIBIDOR DE BET (Divisional expediente 2019-0027.) |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
JP2955358B2 (ja) | 1989-06-09 | 1999-10-04 | ファルマシア・アンド・アップジョン・カンパニー | 中枢神経系活性を有する複素環系アミン |
EP0641320B1 (en) * | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
AU684808B2 (en) * | 1993-07-27 | 1998-01-08 | Pharmacia & Upjohn Company | Heterocyclic amines having central nervous system activity |
JPH1053525A (ja) * | 1996-06-06 | 1998-02-24 | Bitakain Seiyaku Kk | 疼痛治療剤 |
US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
PT1459750E (pt) | 1999-07-01 | 2005-08-31 | Pharmacia & Upjohn Co Llc | (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes |
DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
WO2001015677A2 (en) | 1999-08-31 | 2001-03-08 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
-
2001
- 2001-04-17 AU AU5311401A patent/AU5311401A/xx active Pending
- 2001-04-17 KR KR1020027014072A patent/KR20040007215A/ko not_active Application Discontinuation
- 2001-04-17 JP JP2001578433A patent/JP2004502650A/ja active Pending
- 2001-04-17 DE DE60115872T patent/DE60115872T2/de not_active Expired - Fee Related
- 2001-04-17 NZ NZ531172A patent/NZ531172A/en unknown
- 2001-04-17 WO PCT/US2001/010807 patent/WO2001081343A2/en active IP Right Grant
- 2001-04-17 CN CN01806849A patent/CN1450898A/zh active Pending
- 2001-04-17 AT AT01926590T patent/ATE312608T1/de not_active IP Right Cessation
- 2001-04-17 BR BR0110210-9A patent/BR0110210A/pt not_active IP Right Cessation
- 2001-04-17 AU AU2001253114A patent/AU2001253114B2/en not_active Ceased
- 2001-04-17 ES ES01926590T patent/ES2253370T3/es not_active Expired - Lifetime
- 2001-04-17 EP EP01926590A patent/EP1274430B1/en not_active Expired - Lifetime
- 2001-04-17 NZ NZ522112A patent/NZ522112A/en unknown
- 2001-04-17 US US09/836,660 patent/US6448258B2/en not_active Expired - Fee Related
- 2001-04-17 CN CNA2004100476387A patent/CN1554343A/zh active Pending
- 2001-04-17 NZ NZ531171A patent/NZ531171A/en unknown
- 2001-04-17 CA CA002405565A patent/CA2405565A1/en not_active Abandoned
- 2001-04-17 DK DK01926590T patent/DK1274430T3/da active
- 2001-04-17 CN CNA2004100476391A patent/CN1554341A/zh active Pending
- 2001-04-19 PE PE2001000357A patent/PE20011212A1/es not_active Application Discontinuation
- 2001-04-20 AR ARP010101861A patent/AR028355A1/es unknown
-
2002
- 2002-05-30 US US10/159,913 patent/US6555548B2/en not_active Expired - Fee Related
-
2003
- 2003-03-07 US US10/383,467 patent/US20030191149A1/en not_active Abandoned
- 2003-04-10 AR ARP030101259A patent/AR039633A2/es unknown
- 2003-04-10 AR ARP030101258A patent/AR039632A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US6555548B2 (en) | 2003-04-29 |
JP2004502650A (ja) | 2004-01-29 |
US6448258B2 (en) | 2002-09-10 |
CN1554343A (zh) | 2004-12-15 |
EP1274430B1 (en) | 2005-12-14 |
NZ531171A (en) | 2005-03-24 |
US20020004510A1 (en) | 2002-01-10 |
AU2001253114B2 (en) | 2005-08-25 |
NZ531172A (en) | 2005-07-29 |
CN1554341A (zh) | 2004-12-15 |
DE60115872D1 (de) | 2006-01-19 |
DK1274430T3 (da) | 2006-02-13 |
US20030191149A1 (en) | 2003-10-09 |
KR20040007215A (ko) | 2004-01-24 |
EP1274430A2 (en) | 2003-01-15 |
CN1450898A (zh) | 2003-10-22 |
NZ522112A (en) | 2004-10-29 |
WO2001081343A3 (en) | 2002-02-28 |
AU5311401A (en) | 2001-11-07 |
BR0110210A (pt) | 2003-01-28 |
ATE312608T1 (de) | 2005-12-15 |
CA2405565A1 (en) | 2001-11-01 |
AR039632A2 (es) | 2005-03-02 |
US20020143010A1 (en) | 2002-10-03 |
ES2253370T3 (es) | 2006-06-01 |
DE60115872T2 (de) | 2006-07-13 |
WO2001081343A2 (en) | 2001-11-01 |
PE20011212A1 (es) | 2001-11-21 |
AR028355A1 (es) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039633A2 (es) | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
ES2178943B1 (es) | Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
AR119158A1 (es) | Tratamientos de angioedema hereditario | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
CO5200840A1 (es) | Combinacion de sustancias activas con clonidina | |
BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
UY27018A1 (es) | Derivados de la pirimidina | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
ES2191942T3 (es) | Nueva utilizacion de un antagonista especifico de los receptores 5ht2a. | |
AR029588A1 (es) | Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida | |
PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
AR062784A1 (es) | Tratmiento de los vertigos con acetil -l- leucina | |
CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente | |
UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |